Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Clinical Trial ID NCT00324155

PubWeight™ 118.61‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00324155

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 67.34
2 Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 26.90
3 Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015 5.49
4 Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011 2.89
5 Antibody-based therapeutics to watch in 2011. MAbs 2011 2.00
6 Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010 1.98
7 Antibodies to watch in 2010. MAbs 2010 1.90
8 CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013 1.71
9 Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015 1.66
10 Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2015 1.54
11 Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014 1.32
12 Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res 2010 1.01
13 Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 2014 0.98
14 Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther 2011 0.90
15 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
16 Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 2016 0.84
17 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
18 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
19 Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities. Front Immunol 2012 0.80
20 Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. Br J Cancer 2013 0.80
21 Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma. Adv Ther 2016 0.80
22 Ipilimumab. Drugs R D 2010 0.79
23 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
24 Intellectual property issues of immune checkpoint inhibitors. MAbs 2015 0.75
25 Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother 2016 0.75
Next 100